Investor Handout
Pharmaceuticals

March 2019
Cautionary Statements Regarding Forward-Looking Information

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Innovative Medicines in Areas of High Unmet Medical Need

Therapeutic area focus
- Hematology
- Ophthalmology
- Oncology
- Radiology
- Women’s Health
- Cardiovascular
- Other

Emerging markets exposure
- Established Markets
- Emerging Markets

Global leadership in important therapeutic areas
- No. 1 in Retinal Diseases
- No. 1 in Women’s Health
- No. 1 in Radiology
- No. 2 in Cardiovascular
- No. 2 in Hematology

Leading Brands
- Xarelto
- Jivi
- Kovatry
- Xofogo
- Eylea
- Mirena
- Envso
- Nexavar
- Stivarga
- Gadovist 1.0
- Aspirin Cardio

Emerging markets include Latin America, Asia (w/o Japan, Australia, New Zealand), Africa and Middle East incl. Turkey, Eastern Europe

Sales 2018 €16.7bn
33%
Attractive Sales Growth and Margin Expansion

\[ \begin{array}{|c|c|c|c|c|}
\hline
\text{Year} & \text{Sales} & \text{EBITDA before special items} & \text{EBITDA margin} \\
\hline
2014 & €13.5bn & €4.1bn & 30.2% \\
2015 & €15.3bn & €4.6bn & 30.2% \\
2016 & €16.4bn & €5.3bn & 32.0% \\
2017 & €16.8bn & €5.7bn & 33.9% \\
2018 & €16.7bn & €5.6bn & 33.4% \\
\hline
\end{array} \]

- Attractive sales growth
- Successful commercialization of innovative products, with Xarelto and Eylea becoming blockbuster brands
- Disciplined resource allocation
- Further growth in sales and profitability expected:
  - Sales growth in the range of 4 to 5 percent per annum on average until 2022
  - Further margin expansion to more than 35 percent in 2022

Including Radiology; Sales growth currency and portfolio adjusted; EBITDA margin before special items
Key Drivers for Growth and Margin Expansion

**Focus on key markets**

<table>
<thead>
<tr>
<th>Country</th>
<th>Sales 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>€3.4bn</td>
</tr>
<tr>
<td>PR China</td>
<td>€2.3bn</td>
</tr>
<tr>
<td>Japan</td>
<td>€1.8bn</td>
</tr>
<tr>
<td>Germany</td>
<td>€1.5bn</td>
</tr>
<tr>
<td>France</td>
<td>€0.6bn</td>
</tr>
<tr>
<td>Brazil</td>
<td>€0.3bn</td>
</tr>
</tbody>
</table>

- ~50% of sales growth (2013 - 2018)

**Focus on key brands**

- ~70% of sales growth (2013 - 2018)

**Prudent cost management**

<table>
<thead>
<tr>
<th>Category</th>
<th>2013 - 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>COGS</td>
<td>-280 bps²</td>
</tr>
<tr>
<td>M&amp;S</td>
<td>-700 bps²</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>+270 bps²</td>
</tr>
</tbody>
</table>

Margin¹ up 260 bps (2013 - 2018)

¹ EBITDA margin before special items; bps: Basis points; ² as percentage of sales; R&D costs adjusted by opt-in payment from J&J of about €190million

// Investor Handout Bayer Pharmaceuticals // March 2019
FY 2018 – Pharmaceuticals Driven by Xarelto & Eylea

Sales
in € million; Δ% yoy, Fx & portfolio adj.

<table>
<thead>
<tr>
<th></th>
<th>FY’17</th>
<th>FY’18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>16,847</td>
<td>16,746</td>
</tr>
<tr>
<td>Price</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>+3%</td>
<td></td>
</tr>
</tbody>
</table>

EBITDA
before special items, in € million; Δ% yoy

<table>
<thead>
<tr>
<th></th>
<th>FY’17</th>
<th>FY’18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price</td>
<td>-2%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Volume**: +6%
- **Currency**: -4%
- **Price**: -2%
- **Portfolio**: -0%

- **Key growth products grew by 14%, top 15 products by 6%**
- **Xarelto (+13%) & Eylea (+20%) with continued strong growth**

- **New launches / indications** for Xarelto (CAD/PAD), Vitrakvi (US), Jivi, Kovaltry (China) and Eylea (China DME & wAMD)
- **Darolutamide** with strong efficacy and safety data

- **EBITDA heavily impacted by negative Fx effects of €256m**

EBITDA Margin

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY’17</td>
</tr>
<tr>
<td>FY’18</td>
</tr>
<tr>
<td>33.9%</td>
</tr>
<tr>
<td>33.4%</td>
</tr>
</tbody>
</table>

*Δ% yoy, Fx & portfolio adj.*
Further Growth in Sales and Profitability

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>Outlook 2019</th>
<th>Target 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales/Sales growth</td>
<td>€16.7bn</td>
<td>~4%</td>
<td>CAGR 4-5%</td>
</tr>
<tr>
<td>EBITDA/EBITDA margin</td>
<td>€5.6bn</td>
<td>~34%</td>
<td>&gt;35%</td>
</tr>
</tbody>
</table>

**Key Products**

<table>
<thead>
<tr>
<th>Product</th>
<th>2018</th>
<th>Outlook 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto</td>
<td>€3.6bn</td>
<td>Low teens percentage increase</td>
</tr>
<tr>
<td>Eylea</td>
<td>€2.2bn</td>
<td>High-single-digit percentage increase</td>
</tr>
</tbody>
</table>

2019 Outlook at constant currencies; 2022 targets at constant currencies, not including portfolio measures
EBITDA / EBITDA margin based on EBITDA before special items
### Until 2022
- Delivering on **mid-term growth and margin aspirations**
- Maximizing the potential of the existing portfolio to ensure short- to mid-term growth
- Continued focus on **cost management**
- Re-alignment of R&D activities to sustain long-term growth beyond LoEs

### 2022+
- Realizing the full value of the portfolio until LoEs
- **China** to become our largest pharma market
- Growth of **Vitrakvi, Darolutamide, Finerenone, Vericiguat** and others
- Sourcing of **external innovation**
- Appropriate management of resources
- Expect business to return to market growth after LoE impact

---

LoE: Loss of exclusivity

---

// Investor Handout Bayer Pharmaceuticals /// March 2019
# Focused Leadership Strategy to Deliver Mid-term Targets and to Ensure Long-term Success

<table>
<thead>
<tr>
<th>Relentless Focus</th>
<th>Innovation</th>
<th>Excellence in Execution</th>
</tr>
</thead>
<tbody>
<tr>
<td>// Stringent focus on <strong>key brands</strong> and <strong>markets incl. China</strong></td>
<td>// Supplement organic pipeline with select <strong>in-licensing</strong> and <strong>bolt-on M&amp;A options</strong></td>
<td>// Maintain <strong>operational focus</strong></td>
</tr>
<tr>
<td>// Achieve <strong>category/segment leadership</strong> within <strong>Oncology</strong> and <strong>Cardiovascular</strong></td>
<td>// <strong>Transform innovation model</strong> to ensure long-term success beyond LoEs</td>
<td>// <strong>Deliver on mid-term growth and margin aspirations</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>// <strong>Execute efficiency measures</strong></td>
</tr>
</tbody>
</table>

LoE: Loss of exclusivity

// Investor Handout Bayer Pharmaceuticals /// March 2019
Cardiovascular and Oncology in Focus for Leadership Aspiration

### Cardiovascular
- Xarelto
- Adalat®
- Glucobay
- ASPIRIN®

- Strong heritage and capabilities
- Leading player in Thrombosis
- Major success with state-of-the-art anticoagulant Xarelto

#### Achieve Category / Segment Leadership

### Oncology
- Nexavar
- Vitrakvi
- Xofogo

- Emerging player in Oncology
- Delivered first marketed alpha-therapy, Xofigo
- Pioneering precision medicine in cancer with Vitrakvi

#### Maximize Potential

### Ophthalmology
- EYLEA

- Eylea being a leader in retinal diseases
- First therapeutic sGC modulator with Adempas

### Women’s Health
- Mirena

- Comprehensive product portfolio for Women’s Health: short- and long-acting reversible contraception, gynecological therapies

#### Maintain Leadership

### Radiology & Others
- Ultravist
- Gadovist®
- Avelox

- Maintain leading industry position for Radiology
- Focus on cash flow contribution
Cardiovascular
Xarelto – Continued Growth of a Leading Anticoagulant

- Most broadly indicated anticoagulant for use in venous and arterial thromboembolic conditions
- A leading pharma brand with global sales of €5.2bn in 2018 incl. sales at Johnson & Johnson
- New CAD/PAD indication launching in EU and the US
- Peak sales potential: >€5.0bn
- Further growth driven by:
  - Under-served patient populations
  - Demographics
  - Shift from warfarin
  - New indications targeting patients currently not treated with anticoagulants

Sales in €bn

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales (€bn)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>1.7</td>
</tr>
<tr>
<td>2015</td>
<td>2.3</td>
</tr>
<tr>
<td>2016</td>
<td>2.9</td>
</tr>
<tr>
<td>2017</td>
<td>3.3</td>
</tr>
<tr>
<td>2018</td>
<td>3.6</td>
</tr>
</tbody>
</table>

CAD: Coronary artery disease; PAD: Peripheral artery disease
1 Ex-US sales plus royalty from J&J as reported by Bayer
Xarelto Demonstrates Significant Therapeutic Benefits in CAD/PAD
Potential for Changing the Current Standard of Care

**Efficacy (RRR)**

- **MACE**
  - 24%

- **Stroke**
  - 42%

- **CV Death**
  - 22%

- **MI**
  - 14%

**Safety**

- Low overall bleeding incidence rates, although major bleeding was increased

- No significant increase in fatal or intracranial bleeding

- Combination of Xarelto 2.5 mg bid + aspirin 100 mg od compared to aspirin 100 mg od alone (COMPASS)

- Significant reduction in the relative risk for the primary composite of stroke, myocardial infarction and cardiovascular death (MACE)

- 20% improvement in net clinical benefit

- Provides a larger relative risk reduction than dual anti-platelet strategies

- Xarelto is the only oral anticoagulant that is approved for the prevention of atherothrombotic events in patients with CAD or PAD

---


CAD: Coronary artery disease; PAD: Peripheral artery disease; MACE: Major adverse cardiovascular events; CV: Cardiovascular; MI: Myocardial infarction; RRR: Relative risk reduction

1 Net clinical benefit was defined as the composite of stroke, cardiovascular death, myocardial infarction, fatal bleeding or symptomatic bleeding in a critical organ; 2 Not statistically significant
Oncology
Vitrakvi Provides Novel Tumor-Agnostic Precision Medicine Cancer Therapy

Vitrakvi is an oral, small molecule, highly selective inhibitor of tropomyosin receptor kinases (TRKs).

NTRK gene fusions can lead to cancer and are facilitating tumor growth as oncogenic drivers.

Relevant genetic alteration is estimated to occur in about 0.5 - 1.0% of patients with solid tumors.

FDA approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion.

Distinguished science, in-licensed from Eli Lilly together with 2nd generation TRK inhibitor LOXO-195.

Peak sales potential of >€750 million.

---

NTRK: Neurotrophic receptor tyrosine kinase

---

// Investor Handout Bayer Pharmaceuticals /// March 2019
Vitrakvi Demonstrates Impressive Anti-Tumor Activity
Activity in a Wide Range of Tumors Associated with NTRK Gene Fusions

Objective response rate (N=109)

- Objective response rate: 81% (95% CI 72-88%)
- Best response:
  - Partial response: 63%
  - Complete response: 17%

Maximum change in tumor size according to tumor type (RECIST)

Lassen, U. et al., ESMO 2018

NTRK: Neurotrophic receptor tyrosine kinase; RECIST: Response evaluation criteria in solid tumors
Xofigo – Important Treatment Option in Prostate Cancer

Sales in €m

2014 2015 2016 2017 2018

157 257 331 408 351

First marketed alpha-pharmaceutical

Specifically targeting bone metastases

Approved for the treatment of adults with metastatic castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases¹

Over 51,000 patients worldwide treated so far - Xofigo continues to be an important treatment option in prostate cancer

CRPC: castration resistant prostate cancer

¹ Valid for US. In the EU, the product label is as follows: Xofigo is indicated for the treatment of patients who have had two previous treatments for mCRPC (castrate resistant prostate cancer that has spread to the bone) or who cannot receive other treatments.
Nexavar and Stivarga – Defend and Grow Positions in HCC and CRC

### Nexavar
- Approved for kidney cancer (RCC), liver cancer (HCC) and radioactive iodine refractory differentiated thyroid cancer (DTC)
- Increasing competitive pressure in the US and in Japan
- Strong volume growth in China

### Stivarga
- Approved for metastatic colorectal cancer (mCRC), advanced gastrointestinal stromal tumors (GIST) and 2nd line liver cancer (HCC)
- For HCC, Nexavar as 1st line treatment and Stivarga as 2nd line after progression on Nexavar

---

DTC: differentiated thyroid cancer; GIST: gastrointestinal stromal tumor; HCC: hepatocellular cancer; mCRC: metastatic colorectal cancer; RCC: renal cell carcinoma

---

// Investor Handout Bayer Pharmaceuticals // March 2019
Eylea – A Leader in Retinal Diseases

- A leader in retinal diseases with global brand sales of €5.6bn in 2018 incl. sales at Regeneron
- Approved for the treatment of 5 retinal diseases: wAMD, DME, BRVO, CRVO, mCNV
- Treat and extend dosing regimen with injection intervals of up to 12 weeks or more for wAMD
- Peak sales potential: >€2.5bn
- Further growth driven by:
  - Continued generation of real-life experience in wAMD across key markets and treatment-naïve patient share gains
  - Market expansion in DME

1 Marketed by Bayer ex-US only; 2 As reported by Bayer
wAMD: Wet age related macular degeneration; DME: Diabetic macular edema; BRVO: Branch retinal vein occlusion; CRVO: Central retinal vein occlusion, mCNV: Myopic choroidal neovascularization
Adempas – Pioneering sGC-modulators with Adempas as First-in-Class Product

Sales in €m

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>89</td>
<td>181</td>
<td>254</td>
<td>295</td>
<td>356</td>
</tr>
</tbody>
</table>

- Oral soluble guanylate cyclase (sGC) stimulator approved for two forms of pulmonary hypertension: PAH and CTEPH
- First and only drug receiving marketing authorization for the treatment of CTEPH
- Agreement with Merck & Co. for joint development and commercialization of sGC-modulators in place
- >14,000 patients treated to date
- Peak sales potential: >€500m

1 As of December 2018; 2 As recorded for Bayer
CTEPH: Chronic thromboembolic pulmonary hypertension; PAH: Pulmonary arterial hypertension; sGC: soluble guanylate cyclase

// Investor Handout Bayer Pharmaceuticals // March 2019
Leader in Women’s HealthCare

Comprehensive Product Portfolio in Place

Menopause Management & Gynecological Therapies

- Visanne

Short-acting contraception

Sales 2018 €2.8bn

39%

18%

Long-acting reversible contraception

- Mirena
- Jaydess
- Kyleena

- Leverage potential in developing markets and from life cycle management such as e.g. Yaz Flex

- Established market leader
- Mirena - Intrauterine device for reversible long-term contraception (up to 5 years) and treatment of heavy menstrual bleeding
- Life-Cycle Management:
  - Jaydess: Small low-dose long-acting (up to 3 years) device
  - Kyleena: Long-acting (up to 5 years), low-dose, small device

Menopause Management / Gynecological Therapies

- Continued R&D efforts in areas of high unmet medical need: Endometriosis, Fibroids
Trusted Key Player in Hemophilia

- Kogenate
- Kovaltry
- Jivi

**FVIII replacement therapy**

- **Phase I**
- **Phase II**
- **Marketeted**

- **Number 2 position in Hemophilia with a portfolio of standard half-life (Kogenate, Kovaltry) and extended half-life factor VIII products (Jivi)**

- Kovaltry is a full-length rFVIII product allowing for prophylaxis treatment with as few as two applications per week

- Jivi is the only extended half product to demonstrate effective bleed protection with unique prophylaxis regimen

- **Robust innovation pipeline:**
  - **Anti-TFPI Antibody Bypass Therapy:** Phase II ongoing
  - **Gene Therapy:** Phase 1/2 started end of 2018

---

MoA: mode of action
TFPI: tissue factor pathway inhibitor

// Investor Handout Bayer Pharmaceuticals // March 2019
R&D Pipeline
Re-alignment of R&D-activities to Increase Sustainable R&D Productivity

<table>
<thead>
<tr>
<th>From</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>// <strong>Broad set of indications</strong> in Oncology, Cardiovascular Diseases and Gynecological Therapies</td>
<td>// <strong>Focus on select areas</strong> with high unmet medical need in Oncology, Cardiovascular Diseases and Gynecological Therapies</td>
</tr>
<tr>
<td>// Focus on <strong>functional and technical expertise</strong></td>
<td>// Focus on <strong>deep disease understanding</strong></td>
</tr>
<tr>
<td>// Strong reliance on <strong>small molecules</strong></td>
<td>// <strong>Broader mechanistic approach</strong> beyond therapeutic area focus</td>
</tr>
<tr>
<td>// Majority of <strong>assets sourced internally</strong></td>
<td>// Invest in <strong>new technologies and capabilities</strong></td>
</tr>
<tr>
<td>// Highly <strong>concentrated geographical footprint</strong></td>
<td>// Continue to explore potentially <strong>game-changing innovations</strong> through LEAPS</td>
</tr>
<tr>
<td>// <strong>Internally oriented</strong> resource model</td>
<td>// Increased portion of R&amp;D <strong>assets to be sourced externally</strong> in the future</td>
</tr>
<tr>
<td></td>
<td>// Evolve footprint with <strong>more co-location in science hubs</strong></td>
</tr>
<tr>
<td></td>
<td>// Adapt internal cost base to <strong>free up funds for sourcing inorganic opportunities</strong></td>
</tr>
</tbody>
</table>
Our Pipeline Contains ~50 Projects in Clinical Development

### Phase I (27)
- Cancer / TRK Inhibitor (LOXO-195)
- Cancer / Rogaratinib (pan-FGFR Inhibitor)
- Cancer / PTEFb Inhibitor
- Cancer / ATR Inhibitor
- Cancer / DHODH Inhibitor
- Cancer / Copanlisib (PI3K Inhibitor)
- Cancer / Regorafenib* (multi-Kinase Inhibitor)
- Cancer / Anetumab Raptansine (Mesothelin-ADC)
- Cancer / CD22-Targeted Thorium Conjugate
- Cancer / MSLN-Targeted Thorium Conjugate
- Cancer / CEACAM6 fb Antibody
- Cancer / ILDR2 fb Antibody
- Heart Failure / Vasopressin Receptor Antagonist
- Chronic Kidney Disease / sGC Activator 1
- Chron. Kidney Disease / Vasopressin V1a Receptor Antag.
- Pulmonary Hypertension / sGC Activator 2
- Anti-coagulation / FXIa Inhibitor
- Endometriosis / P2X3 Antagonist 1
- Endometriosis / P2X3 Antagonist 2
- Endometriosis / P2X4 Antagonist
- Endometriosis / Rheumatoid Arthritis / IRAK4 Inhibitor 1
- Hemophilia / FVIII Gene Therapy
- Acute Respiratory Distress Syndrome / sGC Activator 3
- Acute Respiratory Distress Syndrome / PEG-ADM Inhale
- Obstructive Sleep Apnea / TASK Channel-Blocker 1
- Rheumatoid Arthritis / IRAK4 Inhibitor 2

### Phase II (12)
- Urothelial Cancer / Rogaratinib (pan-FGFR Inhibitor)
- Thrombosis / FXI Antisense (IONIS)
- Thrombosis / anti-FXa Antibody
- Peripheral Artery Disease / ARAlpha 2c Receptor Antagonist
- Heart Failure preserved EF / Vericiguat (sGC Stimulator)
- Chronic Kidney Disease / Fulacimstat
- Endometriosis / Vilaprisan (S-PR Modulator)
- Contraception / Combi IUS: LNG (Progestin) + Indomethacin (NSAID)
- Hemophilia / anti-TFPI-Antibody
- Obstructive Sleep Apnea / TASK Channel-Blocker 1
- Persistent Chronic Cough / P2X3 Antagonist 1
- Persistent Chronic Cough / P2X3 Antagonist 2

### Phase III (8)
- Prostate Cancer (mHSPC) / Darolutamide
- Non-Hodgkin Lymphoma / Copanlisib (PI3K Inhibitor)
- Peripheral Artery Disease / Rivaroxaban (FXa Inhibitor)
- Venous Thromboembolism in Children / Rivaroxaban
- Heart Failure reduced EF / Vericiguat (sGC Stimulator)
- Diabetic Kidney Disease / Finerenone (nat MR Antagonist)
- Renal Anemia / Molidustat (HIF-PH Inhibitor)
- Sympt. Uterine Fibroids / Vilaprisan (S-PR Modulator)

As of February 2019
Late-stage Pipeline with Progress in Oncology
Darolutamide met Primary Endpoint in Phase III-trial and FDA-approval of Vitrakvi

<table>
<thead>
<tr>
<th>Indication</th>
<th>Status</th>
<th>Commercial Potential</th>
<th>Clinical Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vitrakvi</strong></td>
<td>// TRK-fusion Cancer <strong>FDA approved / in registration</strong> // PSP &gt;€750m // Clinical program ongoing</td>
<td>// PSP &gt;€1bn</td>
<td></td>
</tr>
<tr>
<td><strong>Darolutamide</strong></td>
<td>// Prostate Cancer // Phase III (nmCRPC) // Phase III (mHSPC) // PSP &gt;€1bn // Completed (ARAMIS, nmCRPC) // Aug 2022e (ARASENS, mHSPC)</td>
<td>// PSP &gt;€0.5bn</td>
<td></td>
</tr>
<tr>
<td><strong>Copanlisib</strong></td>
<td>// Lymphoma // Launched in the US // Phase III // PSP &gt;€1bn</td>
<td>// PSP &gt;€0.5bn</td>
<td></td>
</tr>
<tr>
<td><strong>Finerenone</strong></td>
<td>// Diabetic Kidney Disease // Phase III</td>
<td>// PSP &gt;€1bn</td>
<td></td>
</tr>
<tr>
<td><strong>Vericiguat</strong></td>
<td>// Chronic Heart Failure // Phase III (HFrEF) // Phase II (HFrEF)</td>
<td>// PSP ~€0.5bn</td>
<td></td>
</tr>
</tbody>
</table>

NTRK: Neurotrophic receptor tyrosine kinase; nmCRPC: Non-metastatic castration resistant prostate cancer; mHSPC: Metastatic hormone sensitive prostate cancer; HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction; PSP: Peak sales potential

**Investor Handout Bayer Pharmaceuticals // March 2019**
Darolutamide to Expand Our Position in Prostate Cancer

**Expanding our position in prostate cancer**

<table>
<thead>
<tr>
<th>Disease progression</th>
<th>Non-metastatic</th>
<th>Metastatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local tumor in prostate</td>
<td>Advanced local tumor in prostate</td>
<td>Asymptomatic metastatic disease</td>
</tr>
</tbody>
</table>

**Treatment options**

<table>
<thead>
<tr>
<th>Surgery / EBRT</th>
<th>LHRH</th>
<th>ADT</th>
<th>ADT / Chemo</th>
<th>Chemotherapy</th>
<th>Novel anti-androgens</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Trials</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ARAMIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ARA-SENS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Xofigo</td>
</tr>
</tbody>
</table>

- **Darolutamide** is a novel non-steroidal androgen receptor antagonist in development for the treatment of prostate cancer.
- Met primary endpoint of metastasis-free survival in the ARAMIS trial in non-metastatic CRPC.
- Strong safety profile demonstrated in ARAMIS.
- Phase III trial in metastatic HSPC (ARASENS) ongoing.
- Potential for differentiation:
  - Differentiated chemical structure
  - High binding affinity
  - Negligible blood-brain barrier penetration

CRPC: Castration resistant prostate cancer; HSPC: Hormone sensitive prostate cancer; EBRT: External beam radiation therapy; LHRH: Luteinizing hormone-releasing hormone; ADT: Androgen deprivation therapy.
Darolutamide Significantly Extended Metastasis-free Survival in Men with Castration Resistant Prostate Cancer

Darolutamide showed a positive trend in overall survival (OS), with a 29 percent reduction in the risk of death (HR=0.71, 95% CI 0.50-0.99; P=0.045, median not reached)

All other secondary endpoints also demonstrated a benefit in favor of darolutamide (time to cytotoxic chemotherapy, time to first symptomatic skeletal event)

HR: Hazard ratio; RR: Risk reduction

1N Engl J Med; DOI: 10.1056/NEJMoa1815671

// Investor Handout Bayer Pharmaceuticals /// March 2019
Darolutamide Demonstrated Overall Favorable Safety Profile with Key Adverse Events not Increased Relative to Placebo

Incidence of adverse events comparable between darolutamide and placebo arms

Overall favorable safety and tolerability profile, allowing patients with nmCRPC, who are mainly asymptomatic, to maintain their quality of life – addressing an unmet need for men at this stage of the disease

Other key adverse events of interests were:

<table>
<thead>
<tr>
<th>%</th>
<th>Darolutamide</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue/asthenic condition</td>
<td>15.8</td>
<td>11.4</td>
</tr>
<tr>
<td>Dizziness</td>
<td>4.5</td>
<td>4.0</td>
</tr>
<tr>
<td>Memory impairment</td>
<td>0.5</td>
<td>1.3</td>
</tr>
<tr>
<td>Hypertension</td>
<td>6.6</td>
<td>5.2</td>
</tr>
<tr>
<td>Coronary artery disorders</td>
<td>3.2</td>
<td>2.5</td>
</tr>
<tr>
<td>Heart failure</td>
<td>1.9</td>
<td>0.9</td>
</tr>
</tbody>
</table>

1 N Engl J Med; DOI: 10.1056/NEJMoa1815671
Copanlisib is a Differentiated PI3K-inhibitor for the Treatment of Lymphoma

Key phase II data (CHRONOS-1)¹

Overall response rate in patients with follicular B-cell non-Hodgkin’s lymphoma who had relapsed disease following at least two prior treatments:

<table>
<thead>
<tr>
<th></th>
<th>Copanlisib</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=104</td>
<td></td>
</tr>
<tr>
<td>Overall response rate</td>
<td>59%</td>
</tr>
<tr>
<td>Complete response</td>
<td>14%</td>
</tr>
<tr>
<td>Partial response</td>
<td>44%</td>
</tr>
</tbody>
</table>

Copanlisib had a favorable safety profile with a low rate of severe toxicities overall.

- Phosphatidylinositol-3-kinase (PI3K) inhibitor blocking cellular signal transduction processes crucial for cancer progression
- In development for various forms of lymphoma
- Potential for differentiation:
  - Inhibits different isoforms of PI3K
  - Intravenous administration, thus lower propensity for serious gastrointestinal toxicity
  - Intermittent once weekly dosing
- Launched in the US in 2017 for the treatment of relapsed follicular lymphoma. Registration granted under accelerated FDA approval based on phase II data

¹ Dryling M. et al.: Blood 2017; 130: 2777
Finerenone May Reduce the Risk of CV-mortality and the Progression of Kidney Disease in Patients with Diabetic Kidney Disease

Key phase II data (ARTS-DN\(^1\))

Dose dependent reduction of proteinuria by finerenone when added to RAS blocker therapy in patients with DKD

- Finerenone is a novel non-steroidal MRA under development with a specifically high selectivity and receptor affinity

- Addressing high unmet medical need

- Two phase III trials in diabetic kidney disease underway: FIDELIO DKD (CV study) and FIGARO DKD (renal study)

- Potential for differentiation:
  - First-in-class MRA for treatment of DKD
  - Non-steroidal structure, no interaction with steroid hormone receptors compared to existing MRAs
  - Low risk of hyperkalemia which prohibits the use of marketed MRAs in DKD

MRA: Mineralocorticoid receptor antagonist; RAS: Renin-angiotensin system; CV: Cardiovascular; DKD: Diabetic kidney disease; UACR: Urinary albumin-creatinine ratio

\(^1\) Bakris, G.L. et al., JAMA 2015; 314:884-894.

---

33 // Investor Handout Bayer Pharmaceuticals // March 2019
Vericiguat is a Potentially New Treatment Option on Top of Standard of Care for Patients with Heart Failure

Dose-response relationship between vericiguat dose and reduction in NT-proBNP, a surrogate marker for cardiac function

Key phase II data (SOCRATES-REDUCED\(^1\))

\[ \begin{align*}
\text{PLA} & & 1.25 \text{ mg} & & 2.5 \text{ mg} & & 2.5-5 \text{ mg} & & 2.5-10 \text{ mg} & & \text{Pooled} \\
0 & & 15 & & 30 & & 45
\end{align*} \]

% change in NT-proBNP level from baseline at 12 weeks

First-in-class, direct sGC stimulator addressing the NO-sGC-cGMP pathway, a relevant mechanism in heart failure

Heart failure is still associated with significant mortality risk despite the availability of new therapeutic options

Potential for differentiation:

- New mode of action to be positioned on top of standard of care
- OD dosing and overall favorable safety and tolerability profile

Development in collaboration with Merck & Co.

---

sGC: Soluble guanylate cyclase; NO: Nitric oxide; cGMP: Cyclic guanosinmonophosphate; OD: Once daily; PLA: Placebo; NT-proBNP: N-terminal prohormone of brain natriuretic peptide

\(^1\) Gheorghiade, M. et al: JAMA 2015; 314: 2251-2262
### Expected Launches of Key Pipeline Assets

<table>
<thead>
<tr>
<th>Year</th>
<th>Cardiovascular</th>
<th>Oncology</th>
<th>HEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Xarelto (CAD/PAD)</td>
<td>Vitakvi (TRK-fusion cancer)</td>
<td>Damoctocog (Hemophilia A)</td>
</tr>
<tr>
<td>2019</td>
<td>Finerenone (Diabetic kidney disease)</td>
<td>LOXO-195 (TRK-fusion cancer)</td>
<td>Anti-TFPI (Hemophilia)</td>
</tr>
<tr>
<td>2020</td>
<td>Vericiguat (Heart failure (HFrEF))</td>
<td>Darolutamide (nmCRPC)</td>
<td>FVIII Gene Therapy (Hemophilia A)</td>
</tr>
<tr>
<td>2021</td>
<td>Ped. VTE treatment (EINSTEIN JUNIOR)</td>
<td>Prostate cancer label expansion (mHSPC)</td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td>Heart failure label expansion (HFpEF)</td>
<td>Copanlisib (Lymphoma label expansion (Copanlisib/Rituximab iNHL 2nd line))</td>
<td></td>
</tr>
<tr>
<td>2023+</td>
<td></td>
<td>Damoctocog (Hemophilia A)</td>
<td></td>
</tr>
</tbody>
</table>

First launch in first indication

NTRK: Neurotrophic receptor tyrosine kinase; nmCRPC: Non-metastatic castration resistant prostate cancer; mHSPC: Metastatic hormone sensitive prostate cancer; HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction, iNHL: Indolent Non-Hodgkin Lymphoma. TFPI: Tissue factor pathway inhibitor; WH: Women's Health; HEM: Hematology
# Major Pharma Newsflow in 2019

<table>
<thead>
<tr>
<th>Asset/Project</th>
<th>Mechanism</th>
<th>Intended Indication</th>
<th>Status</th>
<th>Milestone / data / presentation target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darolutamide (ODM-201)</td>
<td>Androgen Receptor Antagonist</td>
<td>Non-metastatic castration-resistant prostate cancer</td>
<td>Phase III</td>
<td>Filings (US, JP, EU) February / March 2019</td>
</tr>
<tr>
<td>Vitrakvi</td>
<td>TRK-Inhibitor</td>
<td>NTRK-Cancer</td>
<td>Launched (US)</td>
<td>EU-Launch in 2019e</td>
</tr>
<tr>
<td>LOXO-195</td>
<td>TRK-Inhibitor</td>
<td>NTRK-Cancer</td>
<td>Phase I/II</td>
<td>Primary completion August 2019e¹</td>
</tr>
<tr>
<td>Xarelto</td>
<td>FXa-Inhibitor</td>
<td>Peripheral artery disease (VOYAGER PAD)</td>
<td>Phase III</td>
<td>Primary completion October 2019e¹</td>
</tr>
<tr>
<td>Vericiguat</td>
<td>sGC-Modulator</td>
<td>Chronic heart failure (VITALITY-HFpEF)</td>
<td>Phase II</td>
<td>Primary completion Dec. 2019e¹</td>
</tr>
</tbody>
</table>

¹ According to clinicaltrials.gov
Investor Handout
Pharmaceuticals

March 2019